ProKidney Corp (PROK)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably
PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA also accepted using eGFR slope analysis for evaluating its potential accelerated approval. PROK believes they'll be ready with their topline slope analysis by Q2 2027. So, there's a clearly outlined regulatory pathway for PROK at this point.
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ProKidney Corp Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 65,578 | $125,074.17 | $108,859.48 | -$16,214.69 | -12.96% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 1.61M | $3.73M | $2.68M | -$1.05M | -28.22% |
| DH Dinan Hu R Squared Ltd | 13,696 | $24,516 | $22,735.36 | -$1,780.64 | -7.26% |
| NAP Norma Angelica Peralta Morales Virtus Family Office LLC | 27,500 | $66,550 | $45,925 | -$20,625 | -30.99% |
| AA Andrew Alkon EntryPoint Capital, LLC | 82,862 | $161,290.56 | $137,550.92 | -$23,739.64 | -14.72% |
ProKidney Corp (PROK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ProKidney Corp ever had a stock split?
ProKidney Corp Profile
| Biotechnology Industry | Healthcare Sector | Bruce Culleton CEO | NASDAQ (CM) Exchange | 74291D104 CUSIP |
| US Country | 204 Employees | - Last Dividend | - Last Split | 12 Jul 2022 IPO Date |
Overview
ProKidney Corp. is a pioneering entity in the biotechnology sector, focusing its efforts on the advancement of cell therapy platforms aimed at the amelioration of chronic kidney diseases. With its inception in 2015, the company has dedicated itself to developing innovative therapeutic solutions from its headquarters in Winston-Salem, North Carolina, USA. The primary mission of ProKidney Corp. is to introduce groundbreaking treatments that offer hope and improved outcomes for patients suffering from various kidney ailments, leveraging the vast potential of cell therapy technologies.
Products and Services
- Renal Autologous Cell Therapy (REACT):
This flagship product embodies the core of ProKidney Corp.'s innovative approach towards tackling chronic kidney diseases. REACT is a cutting-edge therapeutic modality based on the use of autologous homologous cell admixtures. This treatment has successfully completed its Phase I clinical trial, targeting patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). Building upon this initial success, REACT has progressed to Phase III and Phase II clinical trials for addressing moderate to severe diabetic kidney disease, highlighting its potential as a transformative solution for a widespread and impactful health challenge.
